HLA-identical haematopoietic stem cell transplantation for acute leukaemia in children: Less relapse with higher biologically effective dose of TBI

Bone Marrow Transplantation

Volumn 40, Issue 4, 2007, Pages 319-327

  Willemze, A J ^a   Geskus, R B ^b,c   Noordijk, E M ^a   Kal, H B ^d   Egeler, R M ^a   Vossen, J M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; THALIDOMIDE; THYMOCYTE ANTIBODY; VINCRISTINE;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW; CANCER SURVIVAL; CHILD; COLON FLORA; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; OVERALL SURVIVAL; PATIENT CARE; PRIORITY JOURNAL; PROBABILITY; SHORT COURSE THERAPY; WHOLE BODY RADIATION;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; INFANT; KAPLAN-MEIERS ESTIMATE; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; RECURRENCE; RETROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; WHOLE-BODY IRRADIATION;

EID: 34547645996     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705729     Document Type: Article

References (52)

1. Hann IM, Webb DK, Gibson BE, Harrison CJ. MRC trials in childhood acute myeloid leukaemia. Ann Hematol 2004; 83 (Suppl 1): S108-S112.
2. Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. New Engl J Med 2004; 350: 1535-1548.
3. Pui CH, Sandlund JT, Pei D, Campana D, Rivera GK, Ribeiro RC et al. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood 2004; 104: 2690-2696.
4. Woods WG, Neudorf S, Gold S, Sanders J, Buckley JD, Barnard DR et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood 2001; 97: 56-62.
5. Schrappe M, Reiter A, Zimmermann M, Harbott J, Ludwig WD, Henze G et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berfin-Frankfurt-Munster. Leukemia 2000; 14: 2205-2222.
6. Steinherz PG, Gaynon PS, Breneman JC, Cherlow JM, Grossman NJ, Kersey JH et al. Treatment of patients with acute lymphoblastic leukemia with bulky extramedullary disease and T-cell phenotype or other poor prognostic features: Randomized controlled trial from the Children's Cancer Group. Cancer 1998; 82: 600-612.
7. Balduzzi A, Valsecchi Md, Uderzo C. De Lorenzo P, Klingebiel T, Peters C et al. Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: Comparison by genetic randomisation in an international prospective study. Lancet 2005; 366: 635-642.
8. Roy A, Cargill A, Love S, Moorman AV, Stoneham S, Lim A et al. Outcome after first relapse in childhood acute lymphoblastic leukaemia - lessons from the United Kingdom R2 trial. Br J Haematol 2005; 130: 67-75.
9. Badell I, Munoz A, Ortega JJ, Martinez A, Madero L, Bureo E et al. Long-term outcome of allogeneic or autologous haemopoietic cell transplantation for acute lymphoblastic leukaemia in second remission in children. GETMON experience 1983-1998. Bone Marrow Transplant 2005; 35: 895-901.
10. Henze G, Fengler R, Hartmann R. Kornhuber B, Janka-Schaub G, Niethammer D et al. Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM 85). A relapse study of the BFM group. Blood 1991; 78: 1166-1172.
11. Lawson SE, Harrison G, Richards S, Oakhill A, Stevens R, Eden OB et al. The UK experience in treating relapsed childhood acute lymphoblastic leukaemia: A report on the medical research council UKALLR1 study. Br J Haematol 2000; 108: 531-543.
12. Webb DK. Management of relapsed acute myeloid leukaemia. Br J Haeniatol 1999; 106: 851-859.
13. Reiss U, Bolotin E. New approaches to hematopoietic cell transplantation in oncology. Pediatr Clin North Am 2002; 49: 1437-1466.
14. Clift RA, Buckner CD, Appelbaum FR, Bryant E, Bearman SL Petersen FB et al. Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: A randomized trial of two irradiation regimens. Blood 1991; 77: 1660-1665.
15. Bacigalupo A, Vitale V, Corvo R, Barra S, Lamparelli T, Gualandi F et al. The combined effect of total body irradiation (TBI) and cyclosporin A (CyA) on the risk of relapse in patients with acute mycloid leukaemia undergoing allogeneic bone marrow transplantation. Br J Haematol 2000; 108: 99-104.
16. Clift RA, Buckner CD, Appelbaum FR, Sullivan KM, Storb R, Thomas ED. Long-term follow-up of a randomized trial of two irradiation regimens for patients receiving allogeneic marrow transplants during first remission of acute myeloid leukemia. Blood 1998; 92: 1455-1456.
17. Corvo R, Paoli G, Barra S, Bacigalupo A, Van Lint MT, Franzone P et al. Total body irradiation correlates with chronic graft versus host disease and affects prognosis of patients with acute lymphoblastic leukemia receiving an HLA identical allogeneic bone marrow transplant. Int J Radiat Oncol Biol Phys 1999; 43: 497-503.
18. Farag SS, Fehniger TA, Ruggeri L, Velardi A, Caligiuri MA. Natural killer cell receptors: New biology and insights into the graft-versus-leukemia effect. Blood 2002; 100: 1935-1947.
19. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ et al. Graft-versus-leukemia reactions after bone-marrow transplantation. Blood 1990; 75: 555-562.
20. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86: 2041-2050.
21. Boulad F, Steinherz P, Reyes B, Heller G, Gillio AP, Small TN et al. Allogeneic bone marrow transplantation versus chemotherapy for the treatment of childhood acute lymphoblastic leukemia in second remission: a single-institution study. J Clin Oncol 1999; 17: 197-207.
22. Craze JL, Harrison G, Wheatley K, Hann IM, Chessells JM. Improved outcome of acute myeloid leukaemia in Down's syndrome. Arch Dis Child 1999; 81: 32-37.
23. Raimondi SC, Chang MN, Ravindranath Y, Behm FG, Gresik MV, Steuber CP et al. Chromosomal abnormalities in 478 children with acute myeloid leukemia: Clinical characteristics and treatment outcome in a cooperative pediatric oncology group study-POG 8821. Blood 1999; 94: 3707-3716.
24. Stevens RF, Hann IM, Wheatley K, Gray RG. Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: Results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party. Br J Haematol 1998; 101: 130-140.
25. Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. New Engl J Med 1986; 314: 729-735.
26. Vossen JM, Heidt PJ, van den BH, Gerritsen EJ, Hermans J, Dooren LJ. Prevention of infection and graft-versus-host disease by suppression of intestinal microflora in children treated with allogeneic bone marrow transplantation. Eur J Clin Microbiol Infect Dis 1990; 9: 14-23.
27. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 18: 295-304.
28. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-217.
29. van Tol MJ, Langlois vdB, Mesker W, Ouwerkerk-van Velzen MC, Vossen JM, Tanke HJ. Simultaneous detection of X and Y chromosomes by two-colour fluorescence in situ hybridization in combination with immunophenotyping of single cells to document chimaerism after sex-mismatched bone marrow transplantation. Bone Marrow Transplant 1998; 21: 497-503.
30. van Leeuwen JE, van Tol MJ, Joosten AM, Wijnen JT, Verweij PJ, Khan PM et al. Persistence of host-type hematopoiesis after allogeneic bone marrow transplantation for leukemia is significantly related to the recipient's age and/or the conditioning regimen, but it is not associated with an increased risk of relapse. Blood 1994; 83 3059-3067.
31. de Weger RA, Tilanus MG, Scheidel KC, van den Tweel JG, Verdonck LF. Monitoring of residual disease and guided donor leucocyte infusion after allogeneic bone marrow transplantation by chimaerism analysis with short tandem repeats. Br J Haematol 2000; 110: 647-653.
32. Arico M, Valsecchi MG, Camitta B, Schrappe M, Chessells J, Baruchel A et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. New Engl J Med 2000; 342: 998-1006.
33. Uderzo C, Valsecchi MG, Bacigalupo A, Meloni G, Messina C, Polchi P et al. Treatment of childhood acute lymphoblastic leukemia in second remission with allogeneic bone marrow transplantation and chemotherapy: ten-year experience of the Italian Bone Marrow Transplantation Group and the Italian Pediatric Hematology Oncology Association. J Clin Oncol 1995; 13: 352-358.
34. Chen AR, Alonzo TA, Woods WG, Arceci RJ. Current controversies: Which patients with acute myeloid leukaemia should receive a bone marrow transplantation? An American view. Br J Haematol 2002; 118: 378-384.
35. Entz-Werle N, Suciu S, van der Werff ten Bosch J, Vilmer E, Bertrand Y, Bencit Y et al. Results of 58872 and 58921 trials in acute myeloblastic leukemia and relative value of chemotherapy vs allogeneic bone marrow transplantation in first complete remission: The EORTC Children Leukemia Group report. Leukemia 2005; 19: 2072-2081.
36. Gibson BE, Wheatley K, Hann IM, Stevens RF, Webb D, Hills RK et al. Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials. Leukemia 2005; 19: 2130-2138.
37. Creutzig U, Zimmermann M, Ritter J, Reinhardt D, Hermann J, Henze G et al. Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. Leukemia 2005; 19: 2030-2042.
38. Gibson BE, Wheatley K, Hann IM, Stevens RF, Webb D, Hills RK et al. Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials. Leukemia 2005; 19: 2130-2138.
39. Kardos G, Zwaan CM, Kaspers GJ, De Graaf SS, de Bont ES, Postma A et al. Treatment strategy and results in children treated on three Dutch Childhood Oncology Group acute myeloid leukemia trials. Leukemia 2005; 19: 2063-2071.
40. Porter DL, Collins RH, Hardy C, Kernan NA, Drobyski WR, Giralt S et al. Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions. Blood 2000; 95: 1214-1221.
41. Bader P, Klingebiel T, Schaudt A, Theurer-Mainka U, Handgretinger R, Lang P et al. Prevention of relapse in pediatric patients with acute leukemias and MDS after allogeneic SCT by early immunotherapy initiated on the basis of increasing mixed chimerism: A single center experience of 12 children. Leukemia 1999; 13: 2079-2086.
42. Locatelli F, Zecca M, Rondelli R, Bonetti F, Dini G, Prete A et al. Graft versus host disease prophylaxis with low-dose cyclosporine-A reduces the risk of relapse in children with acute leukemia given HLA-identical sibling bone marrow transplantation: Results of a randomized trial. Blood 2000; 95: 1572-1579.
43. Chessells JM, Hall E, Prentice HG, Durrant J, Bailey CC, Richards SM. The impact of age on outcome in lymphoblastic leukaemia; MRC UKALL X and XA compared: A report from the MRC Paediatric and Adult Working Parties. Leukemia 1998; 12: 463-473.
44. Bolwell BJ. Are predictive factors clinically useful in bone marrow transplantation? Bone Marrow Transplant 2003; 32: 853-861.
45. Bader P, Kreyenberg H, Hoelle W, Dueckers G, Handgretinger R, Lang P et al. Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: Possible role for pre-emptive immunotherapy? J Clin Oncol 2004; 22: 1696-1705.
46. Kal HB, Loes vK-H, Heijenbrok-Kal MH, Struikmans H. Biologically effective dose in total-body irradiation and hematopoietic stem cell transplantation. Strahlenther Onkol 2006; 182: 672-679.
47. Bakker B, Massa GG, Oostdijk W, Weel-Sipman MH, Vossen JM, Wit JM. Pubertal development and growth after total-body irradiation and bone marrow transplantation for haematological malignancies. Eur J Pediatr 2000; 159: 31-37.
48. Ranke MB, Schwarze CP, Dopfer R, Klingebiel T, Scheel-Walter HG, Lang P et al. Late effects after stem cell transplantation (SCT) in children - growth and hormones. Bone Marrow Transplant 2005; 35 (Suppl 1): S77-S81.
49. Sanders JE, Guthrie KA, Hoffmeister PA, Woolfrey AE, Carpenter PA, Appelbaum FR. Final adult height of patients who received hematopoietic cell transplantation in childhood. Blood 2005; 105: 1348-1354.
50. Socie G, Curtis RE, Deeg HJ, Sobocinski KA, Filipovich AH, Travis LB et al. New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia. J Clin Oncol 2000; 18: 348-357.
51. Shank B, Chu FC, Dinsmore R, Kapoor N, Kirkpatrick D, Teitelbaum H et al. Hyperfractionated total body irradiation for bone marrow transplantation. Results in seventy leukemia patients with allogenic transplants. Int J Radiat Oncol Biol Phys 1983; 9: 1607-1611.
52. Cosset JM, Socie G, Dubray B, Girinsky T, Fourquet A, Gluckman E. Single dose versus fractionated total body irradiation before bone marrow transplantation: Radiobiological and clinical considerations. Int J Radiat Oncol Biol Phys 1994; 30: 477-492.